Navigation Links
Recent Study Shows Leukothera™ Combined with Other Agents Has Enhanced Anti-Leukemia Effects
Date:6/27/2011

NEW BRUNSWICK, N.J., June 27, 2011 /PRNewswire/ -- Recent findings published in the scientific journal Leukemia Research (http://www.sciencedirect.com/science/article/pii/S0145212611002505), showed that when combined with standard anti-leukemia agents, the biological activity of LeukotheraTM, a drug candidate under development by Actinobac Biomed, Inc., showed synergistic anti-leukemia effects.

The outcome of these in vitro experiments demonstrated that combining LeukotheraTM with such widely employed drugs as etoposide, mitoxantrone, daunorubicin, busulfan and imatinib killed leukemia cells much more effectively than when the agents were used alone.  LeukotheraTM is a natural biologic agent that specifically targets malignant and/or inflammatory white blood cells involved in disease.  

Dr. Scott Kachlany, founder of Actinobac Biomed, explained. "Drug combination therapies for cancer are now frequently considered by oncologists due to their many advantages, which include the possibility of reducing doses of toxic chemotherapeutic agents and a lower chance of developing drug resistance," he said.  "The biological mechanism of LeukotheraTM differs from that of other cancer drugs so including it to blood cancer treatment protocols may be a highly effective strategy."

Actinobac Biomed, Inc. was founded in 2009 with financial backing from Foundation Venture Capital Group, LLC, to develop commercial products based upon technology developed at the University of Medicine and Dentistry of New Jersey.  The company has exclusively licensed the rights to develop LeukotheraTM as a therapeutic agent for the treatment of hematologic malignancies, autoimmune and inflammatory diseases and HIV infection.

"We provided early seed funding to Actinobac because we are convinced that they are working on breakthrough research that can make a huge difference for people suffering with leukemia and other diseases," said James M. Golubieski, president of Foundation Venture Capital Group (www.foundationventure.com), an affiliate of New Jersey Health Foundation.  

For more information about Foundation Venture Capital Group, contact Jim Golubieski at (908) 731-6601 or jgolubieski@njhf.org.

For more information or to explore ways in which to partner with Actinobac, contact them at (732) 371-2694, info@actinobac.com or visit www.actinobac.com.


'/>"/>
SOURCE Foundation Venture Capital Group, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Particle Sciences Develops Proprietary Nasal Delivery Formulation Used in Neurelis Recently Announced Successful Phase I Pharmacokinetic Study of NRL-01 (intranasal diazepam)
2. Cardium Announces Cedars-Sinai Heart Institute as the SPECT Imaging Core Lab for the Recently Announced Generx® Phase 3 Clinical Registration Study in the Russian Federation
3. Metabolic Solutions Development Company to Present Recent Findings on the Therapeutic Potential of Increasing Brown Fat in the Treatment of Diabetes at Annual American Diabetes Association Conference
4. FDA Classifies Recent Terumo CVS Recall of Coronary Ostia Cannulae as Class I Action
5. Aethlon Medical to Discuss Recent Progress at the LHA Life Sciences & Medical Technologies Virtual Conference on June 16
6. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
7. A Recent Study by ITGs Majestic Market Research Indicates a Strong Launch for Gilenya in Spite of Its Time-Consuming Initiation Process
8. In a New Audio Interview at SmallCapVoice.com, Gerard Dab, Chairman and CEO of Visual Healthcare Corp., Provides Details Regarding Recent News
9. Applied Medical Sues Covidien, Asserting Recently Issued Universal Seal Trocar Patent
10. Instacare Corp. Board of Directors Considers Recent Merger Proposal Inadequate
11. Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... CITY, Calif. , Feb. 16, 2017 /PRNewswire/ ... a specialty pharmaceutical company focused on the development ... of moderate-to-severe acute pain, announced that Vincent ... officer and a member of the company,s board ... Angotti brings over two decades of experience leading ...
(Date:2/16/2017)... 2017 Research and Markets has announced the ... & Trends - Function, Application, Cancer Type, Technology - Forecast to ... ... is poised to grow at a CAGR of around 28.6% over ... Some of the prominent trends that the market ...
(Date:2/16/2017)... -- WHAT: PerfectServe™ is hosting ... system IT professionals. From making sense of MACRA to optimizing ... participants to prepare for new policies and technologies.    ... WEBINAR TIME ... Webinar: Making Sense of MACRA   Click here ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... While EHR data ... has introduced an innovative workstation designed to reduce nursing fatigue while enhancing productivity. ... EHR Workstation offers a lightweight, highly mobile, multi-functional alternative to the limitations of ...
(Date:2/17/2017)... ... February 17, 2017 , ... For the first time, International ... the exhibit floor for the 2017 HIMSS Conference & Exhibition at ... 2017, more than 40,000 healthcare industry professionals are expected at the conference, where ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... to Prevent a Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 ... manufacturers distinguish between corrective action (CA) and preventive action (PA)? , The methods ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... 2017 season , Trinity Health and the U.S. Soccer Foundation announced today that ... in underserved communities. Soccer for Success, the Foundation’s soccer mentoring program, teaches kids ...
(Date:2/17/2017)... ... 2017 , ... PrideStaff, a national staffing organization, is pleased ... Industry Analysts' 2017 "Staffing 100 North America" list. , Now in its ... the staffing industry over the last twelve months. Industry insiders and observers nominate ...
Breaking Medicine News(10 mins):